Browsed by
Tag: NASDAQPHAS

What Kind Of Investors Own Most Of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS)?

What Kind Of Investors Own Most Of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS)?

If you want to know who really controls PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

PhaseBio Pharmaceuticals is not a large company by global standards. It has a market capitalization of US$109m, which means it wouldn’t have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about PhaseBio Pharmaceuticals.

View our latest analysis for PhaseBio Pharmaceuticals

What Does The Institutional Ownership Tell Us About PhaseBio Pharmaceuticals?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in PhaseBio Pharmaceuticals. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there’s always a risk that they are in a ‘crowded trade’. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see PhaseBio Pharmaceuticals’ historic earnings and revenue below, but keep in mind there’s always more to the story.

earnings-and-revenue-growth

We note that hedge funds don’t have a meaningful investment in PhaseBio Pharmaceuticals. The company’s largest shareholder is

Read the rest